| 证券代码：002022 | 证券简称：科华生物 | | --- | --- | | 债券代码：128124 | 公告编号：2024-046 债券简称：科华转债 | 上海科华生物工程股份有限公司 关于 2024 年第一季度可转债转股情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： | 证券代码：002022 | | | | | | | | | | 证券简称：科华生物 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 债券代码：128124 | | | | | | | | | | 债券简称：科华转债 | | 转股价格：人民币 | | 20.64 | | | 元/股 | | | | | | | 转股期限：2021 | 年 | 2 | 月 | 3 | 日至 | 2026 | 年 7 | 月 | 27 | 日 | 根据《深圳证券交易所股票上市规则》、《深圳证券交易所上市公司自律监管 指引第 15 号——可转换公司债券》的有关规定，上海科华生物工程股份有 ...

2024 年 3 月 20 日，公司召开 2024 年第一次临时股东大会，选举产生了公司第十届董事会全 体董事和第十届监事会非职工代表监事，并通过了修订《公司章程》等议案。同日，公司召开第十 1 根据公司发布的《上海科华生物工程股份有限公司详式权益变动报告书》，《表决权委托协议》项下委托权利的委托期限可由珠海保联 和西安致同协商一致终止，否则自协议生效之日起至如下情形发生之日（以孰早者为准）止：1）本协议生效之日起满 6 年之日；2）除 去委托股份数量，按任一方直接与间接持有的科华生物股份所对应的表决权占科华生物总表决权的比例计算，西安致同表决权比例超过 珠海保联达 10%（含本数），且西安致同基于其所持有的股份所对应的表决权，能够并已经实际取得科华生物实际控制权与实际控制地 位的当日，但前述珠海保联表决权比例因被强制执行或平仓而减少的，不得计算在内。 联合〔2024〕1810 号 联合资信评估股份有限公司关于上海科华生物工程股份有限公司控制权 发生变更及董事会、监事会完成提前换届选举等事项的关注公告 联合资信评估股份有限公司（以下简称"联合资信"）受上海科华生物工程股份有限公司（以 下简称"公司"）委托对其 ...

Company Overview - Shanghai Kehua Bio-engineering Co., Ltd. was established in 1981 and is the first IVD listed company on the Shenzhen Stock Exchange [2] - The company specializes in the R&D, production, and sales of in vitro diagnostic reagents and medical testing instruments, covering molecular diagnostics, biochemical diagnostics, immunodiagnostics, and point-of-care testing (POCT) [2][3] - Kehua Bio has approximately 850 domestic and international registrations/certifications for its products, making it one of the most comprehensive companies in the IVD industry [2] Market Presence - The company has a coverage rate of about 60% in tertiary hospitals and 40% in blood stations in China, with nearly 900 clients in disease control centers and thousands of long-term partnerships with domestic and international agents [3] - Products have been exported to over 100 countries and regions worldwide [3][4] Sales Strategy - The sales model combines "mainly distribution, supplemented by direct sales," leveraging a broad network of distributors and a professional marketing team [3] - The company collaborates with various imported brands to provide comprehensive IVD products and services [3] Product Development and Market Strategy - Kehua Bio is actively adjusting its product strategy to cover multiple methodologies, including biochemical, immunofluorescence, molecular, and mass spectrometry [3][4] - The company aims to establish local service teams in key overseas markets, enhancing its global presence and brand recognition [4][5] Share Buyback Program - The company announced a share buyback plan on October 30, 2023, with a total fund of no less than RMB 100 million and no more than RMB 200 million, at a price not exceeding RMB 11 per share [4] - As of February 29, 2024, the company had repurchased 7,357,900 shares, accounting for 1.43% of the total share capital, with a transaction amount of RMB 60,036,310.16 [4] Future Development and Challenges - The company plans to focus on the animal market, including economic and pet animals, with a comprehensive solution covering biochemical, immunological, molecular, and coagulation methodologies [5] - In response to industry competition and trends such as centralized procurement and domestic substitution, the company aims to enhance its market influence and expand its market share [5]

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB, representing a year-over-year growth of 20%[15]. - The company's operating revenue for 2023 was ¥2,428,075,213.95, a decrease of 65.16% compared to ¥6,969,862,627.72 in 2022[22]. - The net profit attributable to shareholders for 2023 was -¥234,014,886.40, representing a decline of 124.09% from ¥970,845,080.02 in 2022[22]. - The basic earnings per share for 2023 was -¥0.4550, down 124.09% from ¥1.8878 in 2022[23]. - The total assets at the end of 2023 were ¥6,807,739,866.34, a decrease of 22.81% from ¥8,813,157,013.32 at the end of 2022[23]. - The net cash flow from operating activities for 2023 was -¥474,894,786.47, a decline of 122.05% compared to ¥2,153,632,187.55 in 2022[22]. - In 2023, the company's total revenue was approximately ¥2.43 billion, a decrease of 65.16% compared to ¥6.97 billion in 2022[63]. - The domestic revenue accounted for 85.30% of total revenue, amounting to ¥2.07 billion, down 67.16% from ¥6.31 billion in the previous year[63]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[15]. - The company has outlined a future outlook projecting a revenue growth of 25% for the next fiscal year, driven by new product launches and market expansion strategies[15]. - The company is actively seeking opportunities in overseas markets to mitigate challenges posed by geopolitical conflicts and to find new growth points[39]. - The company aims to expand its home self-testing product market, focusing on respiratory, digestive, and reproductive health, integrating digital devices and software to create a personal health management ecosystem[103]. - The company is set to expand its international market presence, particularly in emerging markets, by tailoring technology, product design, channels, pricing, and services to local market characteristics[103]. Research and Development - Investment in R&D has increased by 30%, focusing on innovative diagnostic technologies and enhancing product offerings[15]. - The company has a strong focus on R&D, with significant investments in biochemistry, immunology, molecular diagnostics, and POCT[53]. - R&D investment amounted to ¥317,543,861.24 in 2023, a decrease of 2.82% from ¥326,744,992.52 in 2022, while the R&D investment as a percentage of operating revenue increased significantly to 13.08% from 4.69%[75]. - The company has developed high-sensitivity nucleic acid testing reagents for HBV, HCV, HIV-1, and HIV-2, enhancing its product portfolio in the molecular diagnostics sector[51]. - The company has established partnerships with three leading universities for collaborative research, enhancing innovation capabilities[141]. Product Development and Launches - The company has successfully launched a new line of immunodiagnostic products, contributing to a 5% increase in market share in the domestic market[15]. - The company has launched a portable four-channel real-time fluorescence quantitative PCR instrument, enhancing its product offerings in the pet and livestock markets[74]. - New product launches include a cutting-edge medical device expected to generate an additional 300 million RMB in revenue in 2024[141]. - The company has launched the Polaris series of biochemical luminescence platforms, which supports modular connections and meets the needs of various medical institutions[58]. - The company has developed multiple diagnostic kits, including the free light chain K and λ, which have been certified for market release, enhancing the competitiveness of its kidney function product line[73]. Governance and Management - The company has implemented a robust corporate governance structure, including a board of directors and specialized committees to ensure effective decision-making and compliance[114]. - The company maintains independence from its major shareholder, ensuring that significant decisions are made autonomously[116]. - The company appointed a new president, Mr. Li Ming, effective from April 3, 2023, following the resignation of Ms. Chen Chao from the position[128]. - The board of directors held a total of 12 meetings during the reporting period, with various resolutions disclosed in multiple financial news outlets[145]. - The company has established independent departments for various functions, including sales, R&D, and finance, ensuring no overlap with major shareholders' operations[121]. Financial Management and Investments - The company raised a total of RMB 738 million through the issuance of convertible bonds, with a net amount received of RMB 718.53 million after deducting issuance costs[92]. - The company has provided guarantees totaling CNY 10,000 million to its subsidiaries during the reporting period, with an actual occurrence of CNY 1,000 million[197]. - The company has entrusted financial management with a total amount of CNY 165,700 million, including CNY 120,700 million from self-owned funds and CNY 15,000 million from raised funds[199]. - The company has not engaged in any significant asset or equity acquisition transactions during the reporting period[186]. - The company has not reported any significant changes in cash asset management strategies[198]. Compliance and Risk Management - The company emphasizes the importance of compliance with industry regulations, as changes in regulatory policies could adversely affect its operations[106]. - The company has established a management system for hedging operations, ensuring compliance with operational norms and risk control measures[88]. - The company has implemented measures to monitor and control risks associated with foreign exchange hedging, including regular audits and compliance checks[88]. - The company has established a comprehensive quality management system, ensuring compliance with IVD industry regulations and enhancing customer satisfaction[55]. - The company has not reported any significant discrepancies between its governance practices and the regulations set forth by the China Securities Regulatory Commission[119]. Employee Engagement and Development - The company emphasizes employee rights and development, providing training and a supportive work environment[171]. - The company has a training system in place that includes onboarding for new employees and ongoing training for current staff to enhance overall capabilities[154]. - The company held its first employee representative meeting on June 19, 2023, and elected Ms. Chen Dunfang as the employee supervisor[129]. - The company has seen a 7.70% decrease in R&D personnel, with the total number dropping from 675 in 2022 to 623 in 2023, while the proportion of R&D staff increased from 24.92% to 28.96%[74]. - The company has a diverse compensation policy to attract and retain talent, aligning employee contributions with their compensation[153].

上海科华生物工程股份有限公司 审计报告 大华审字[2024]0011000620 号 大 华 会 计 师 事 务 所 (特 殊 普 通 合 伙 ) DaHuaCertifiedPublicAccountants（SpecialGeneralPartnership） 上海科华生物工程股份有限公司 ［右键单击上一行首，选择更新域键入公司名称的全称］ 科华生物 ［右键单击上一行首，选择更新域键入公司名称的简称］ 上海科华生物工程股份有限公司 审计报告及财务报表 （2023 年 1 月 1 日至 2023 年 12 月 31 日止） | | 目录 | 页次 | | --- | --- | --- | | 一、 | 审计报告 | 1-8 | | 二、 | 已审财务报表 | | | | 合并资产负债表 | 1-2 | | | 合并利润表 | 3 | | | 合并现金流量表 | 4 | | | 合并股东权益变动表 | 5-6 | | | 母公司资产负债表 | 7-8 | | | 母公司利润表 | 9 | | | 母公司现金流量表 | 10 | | | 母公司股东权益变动表 | 11-12 | | | 财务报表附注 | 1- ...

上海科华生物工程股份有限公司 独立董事2023年度述职报告 （郑传芳） 各位股东及股东代表： 本人作为公司的独立董事，根据《中华人民共和国公司法》（以下简称"《公 司法》"）、《中华人民共和国证券法》以下简称"《证券法》"、《上市公司治理准则》、 《上市公司独立董事管理办法》等有关法律法规和《上海科华生物工程股份有限 公司章程》（以下简称"《公司章程》"）、《上海科华生物工程股份有限公司独立董 事工作制度》（以下简称"《独立董事工作制度》"）的要求，本着勤勉尽职的态度， 谨慎、认真、负责、忠实地履行了独立董事的职责，在2023年6月28日至2023年 12月31日履职期间（以下简称"履职期间"）出席了召开的全部董事会会议，运 用自身的专业知识，对公司的科学决策和规范运作提出意见和建议，积极发挥了 独立董事作用，切实维护了公司及股东特别是广大中小股东的利益。现将本人履 职期间履职情况述职如下： 一、基本情况 本人郑传芳，1966年出生，中国国籍，无境外永久居留权，硕士研究生学历， 注册会计师，特许公认会计师(ACCA),曾任电子工业部第四十四研究所工程师、 深圳飞通光电子技术有限公司总会计师、财务总监、深圳新飞 ...

| 证券代码：002022 | 证券简称：科华生物 | | | --- | --- | --- | | 债券代码：128124 | 债券简称：科华转债 | 公告编号：2024-037 | 上海科华生物工程股份有限公司 关于 2023 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 上海科华生物工程股份有限公司（以下简称"公司"）于 2024 年 3 月 21 日 召开第十届董事会第二次会议和第十届监事会第二次会议，审议通过了《关于 2023 年度利润分配预案的议案》，该议案尚需提交公司 2023 年度股东大会审议。 现将相关情况公告如下： 一、2023 年度利润分配预案的基本情况 经大华会计师事务所（特殊普通合伙）审计，公司 2023 年度实现归属于母 公司的净利润-23,401.49 万元，母公司单体实现净利润 4,163.79 万元。2023 年 末母公司实际可供分配的利润为 185,694.60 万元。 为实现公司持续、稳定、健康发展，更好地维护全体股东的长远利益，经审 慎研究，公司拟定 2023 年利润分配预案为：2023 年度 ...

根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要 求（以下简称"企业内部控制规范体系"），上海科华生物工程股份有限公司（以 下简称"科华生物"或"公司"）结合公司内部控制制度和评价办法，在内部控 制日常监督和专项监督的基础上，对公司 2023 年 12 月 31 日（内部控制评价报 告基准日）的内部控制有效性进行了评价。 一、重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其 有效性，并如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建 立和实施内部控制进行监督。管理层负责组织领导企业内部控制的日常运行。公 司董事会及全体董事保证本报告内容不存在任何虚假记载、误导性陈述或重大遗 漏，并对报告内容的真实性、准确性和完整性承担个别及连带法律责任。 二、内部控制评价结论 上海科华生物工程股份有限公司 2023 年度内部控制自我评价报告 根据公司财务报告内部控制重大缺陷的认定标准，于内部控制评价报告基准 日，公司未发现财务报告内部控制重大缺陷，董事会认为，公司已按照企业内部 控制规范体系和相关规定的要求在所有重大方面保持了有效的财务报告内部控 制。 根据公司非财务 ...

| 证券代码：002022 | 证券简称：科华生物 | | | --- | --- | --- | | 债券代码：128124 | 债券简称：科华转债 | 公告编号：2024-040 | 上海科华生物工程股份有限公司（以下简称"公司"）于2024年3月21日召开 第十届董事会第二次会议，审议通过了《关于公司及子公司使用自有资金进行现 金管理的议案》，同意公司及全资、控股子公司（均为合并报表范围内的子公司， 以下统称"子公司"）在不影响公司自身正常经营的情况下，使用合计不超过人 民币120,000万元的暂时闲置自有资金进行现金管理，投资于安全性高、流动性 好、风险低、产品投资期限最长不超过12个月的理财产品；并授权公司董事长或 管理层在额度范围内行使相关决策权、签署相关法律文件，同时授权公司财务部 门具体实施相关事宜。现将相关情况公告如下： 一、 现金管理情况概述 上海科华生物工程股份有限公司 关于公司及子公司使用自有资金进行现金管理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1、投资种类：安全性高、流动性好、风险低、产品投资期限最长 ...

上海科华生物工程股份有限公司 独立董事2023年度述职报告 （徐宏） 各位股东及股东代表： 本人作为公司的独立董事，根据《中华人民共和国公司法》（以下简称"《公 司法》"）、《中华人民共和国证券法》以下简称"《证券法》"、《上市公司治理准则》、 《上市公司独立董事管理办法》等有关法律法规和《上海科华生物工程股份有限 公司章程》（以下简称"《公司章程》"）、《上海科华生物工程股份有限公司独立董 事工作制度》（以下简称"《独立董事工作制度》"）的要求，本着勤勉尽职的态度， 谨慎、认真、负责、忠实地履行了独立董事的职责，在2023年6月28日至2023年 12月31日履职期间（以下简称"履职期间"）出席了召开的全部董事会会议，运 用自身的专业知识，对公司的科学决策和规范运作提出意见和建议，积极发挥了 独立董事作用，切实维护了公司及股东特别是广大中小股东的利益。现将本人履 职期间履职情况述职如下： 一、基本情况 本人徐宏，1979年出生，中国国籍，无境外永久居留权，毕业于中国人民大 学，博士研究生学历，现为华东政法大学企业合规研究中心主任，涉外法治研究 院研究员，硕士生导师。2010年6月至2012年6月挂任安徽省安 ...